Loading…
← CockpitCompetitor Analysis › 2480.HK Beijing Luzhu Biotechnology Co., Ltd. Class HOpen in the cockpit ↗

Beijing Luzhu Biotechnology Co., Ltd. Class H2480.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Biotechnology
Momentum strong 72
Mkt cap
$396M
US dollars, full cap
Free float
22%
of shares outstanding
$/day
$391
20-day average traded
Fwd P/E
26.2×
forward earnings
ROIC−WACC
-25.7 pp
WACC 6.2%
Hurdle
n/a
no reverse DCF
Next earnings
126 days
24 Mar 2027
Close · HKDHK$15.40
1D0.0%
1W+0.5%
1M0.0%
3M+17.6%
6M-32.9%
YTD-34.8%
1Y-33.7%
ATR %0.8%
52w lowhigh40.7% off high

What Beijing Luzhu Biotechnology does

Employees: 193

Beijing Luzhu Biotechnology at a glance

Size Beijing Luzhu Biotechnology (2480.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $396M, the 813th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$15.40 on 18 Nov 2026.

Performance Over six months the shares fell 32.9%, against -23.6% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 8th lowest of 21 in its peer set.

Valuation It trades at 26.2× forward earnings against a peer median of 50.1× (3rd cheapest of 5).

Capital Return on invested capital runs 25.7 points below its cost of capital (6.2% WACC).

Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 752480.HK 70
Six months, rebased to 100: Beijing Luzhu Biotechnology against the median of its 20 peers (local-currency closes).

Beijing Luzhu Biotechnology financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$0HK$0HK$0HK$0HK$0
Revenue growth—————
Gross profit-HK$41.1M-HK$33.8M-HK$27.1M-HK$17.8M-HK$11.5M
EBITDA-HK$106M-HK$128M-HK$190M-HK$269M-HK$195M
Net income-HK$150M-HK$163M-HK$182M-HK$276M-HK$843M
Free cash flow-HK$176M-HK$211M-HK$193M-HK$300M-HK$387M
Capital expenditureHK$56.3MHK$66.5MHK$107MHK$96.3MHK$299M
Total debtn/aHK$304MHK$71.9MHK$21.2MHK$12.6M

Quarterly statements and history in the cockpit →

Beijing Luzhu Biotechnology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%-20%-10%0%300683688098688687PNV116730096633786998ALEC688238PRTCEPRX688163456160CADL47683068831730038165474760602480.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Beijing Luzhu Biotechnology is the large dot.

Beijing Luzhu Biotechnology competitors and peer comparison

How Beijing Luzhu Biotechnology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Beijing Luzhu Biotechnology against its 20 peers (data as of 18 Nov 2026)
Measure2480.HKPeer medianRank in peer set
1-month return0.0%-14.1%3rd highest of 21
6-month return-32.9%-23.6%8th lowest of 21
Distance from 52-week high-40.7%-44.7%10th highest of 21
Forward P/E26.2×50.1×3rd cheapest of 5
ROIC minus cost of capital-25.7 pp-9.2 pp5th lowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Beijing Luzhu Biotechnology 2480.HKHong Kong$396M-33%n/an/a26.2×n/an/a
Wuhan Hiteck Biological Pharma 300683.SZChina$395M-41%-30%-27%n/an/an/a
Shanghai Shen Lian Biomedical 688098.SSChina$402M-22%-17%-16%n/an/an/a
Beijing Kawin Technology Share-Holding 688687.SSChina$391M-20%+6%-2%16.2×36.6%+8.9%
Polynovo PNV.AXAustralia$388M-34%+13%5%84.0×51.9%+37.6%
Jacobio Pharmaceuticals 1167.HKHong Kong$404M-24%+286%68%5.7×-18.8%-36.1%
Hubei Goto Biopharm 300966.SZChina$386M-16%+6%-10%n/an/an/a
Hanx Biopharmaceuticals (Wuhan) 3378.HKHong Kong$409M-24%n/an/an/an/an/a
Edding Genor 6998.HKHong Kong$410M-35%+1,418%26%n/a-15.3%+197.3%
Alector ALECUnited States$383M+21%+151%25%n/an/an/a
Shanghai Obio Technology (Group) 688238.SSChina$414M-5%+20%-79%n/an/an/a
PureTech Health PRTC.LUnited Kingdom$378M-15%-4%-1,617%n/an/an/a
Eupraxia Pharmaceuticals EPRX.TOCanada$416M+1%n/an/an/an/an/a
Shanghai Serum Bio-Technology 688163.SSChina$416M-34%-1%26%n/an/an/a
G2GBIO 456160.KSSouth Korea$416M-53%-45%-2,884%n/an/an/a
Candel Therapeutics CADLUnited States$417M-31%n/an/an/an/an/a
Rznomics 476830.KSSouth Korea$418M-76%-65%-1,112%n/an/an/a
Shanghai ZJ Bio-Tech 688317.SSChina$422M-22%-10%-72%n/a4.0%-62.3%
Guangdong Vtr Bio-Tech 300381.SZChina$370M-31%0%-4%n/an/an/a
Medigen Vaccine Biologics 6547.TWOTaiwan$424M-8%+44%-5%170.0×n/an/a
Onconic Therapeutics 476060.KSSouth Korea$368M-49%+179%21%n/a0.6%+725.2%

Questions

Which companies are Beijing Luzhu Biotechnology's closest peers?
The cockpit's peer set: Wuhan Hiteck Biological Pharma (300683.SZ), Shanghai Shen Lian Biomedical (688098.SS), Beijing Kawin Technology Share-Holding (688687.SS), Polynovo (PNV.AX), Jacobio Pharmaceuticals (1167.HK), Hubei Goto Biopharm (300966.SZ), Hanx Biopharmaceuticals (Wuhan) (3378.HK), Edding Genor (6998.HK).
Is Beijing Luzhu Biotechnology expensive compared with its peers?
On forward p/e it trades at 26.2× against a peer median of 50.1×, 3rd cheapest of 5 in its peer set.
How has Beijing Luzhu Biotechnology stock performed?
Over six months to 18 Nov 2026 the shares returned -32.9% against -23.6% for the median peer; over one year -33.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.